Improving
outcomes for people with CML globally
The International CML Foundation
The International CML Foundation (iCMLf) is on a mission to improve outcomes for patients with CML, globally.
Founded by a dedicated group of hematologists, we are committed to ensuring every patient with CML, no matter where they are in the world, receives the best possible care. We foster international collaboration to elevate knowledge, enhance diagnostics, and drive ground-breaking research.
As a charitable foundation with a global reach, we strive to empower physicians, researchers and patients alike, in the collective pursuit of a cure.
Join us and contribute to a world where a cure for CML is not just a hope, but a reality.
Led by international CML experts:
› Professor Jorge Cortes, Augusta, USA
› Professor Jane Apperley, London, UK
› Professor Brian Druker, Portland, USA
› Professor Andreas Hochhaus, Jena, Germany
› Professor Timothy Hughes, Adelaide, Australia
› Professor Hemant Malhotra, Jaipur, India
› Professor Michael Mauro, New York, USA
› Dr Katia Pagnano, Campinas, Brazil
› Professor Jerald Radich, Seattle, USA
› Professor Giuseppe Saglio, Turin, Italy
› Professor Charles Schiffer, Detroit, USA
What we do
Everything we do centres on three main goals:
Share BEST PRACTICE and enable collaboration between global and regional CML experts, so that people with CML get the BEST POSSIBLE TREATMENT with the resources available.
INCREASE THE RESOURCES AVAILABLE to research, diagnose and treat CML, particularly in low and middle-income countries.
Utilise the i CMLf ’S GLOBAL RESEARCH NETWORK to shift the treatment paradigm towards a cure.
The work that the iCMLf does will help physicians and patients for many years to come. It is an understatement to say the iCMLf is an organisation which really makes a difference to patients lives.
Professor Nirmalya Roy Moulik
Pediatric Oncology Tata Memorial Hospital,
India
Enhance best practice CML management
Uniting healthcare professionals worldwide, these programs bridge knowledge gaps in CML management, ensuring access to the latest advancements and best practices.
John Goldman Meeting
In every way, the iCMLf has improved physician education around the world. But the biggest impact of the iCMLf is the benefit to patients. The iCMLf has shown that just a few people who are committed to the disease can impact the world.
Dr Zeba Aziz Professor of Oncology Consultant Hematologist
Hameed Latif Hospital, Pakistan
Regional Discussion Groups
Preceptorships
Global health disparities disproportionately affect outcomes for people with CML in low and middle-income countries (LMIC’s). Our work has a particular focus on clinicians working in LMIC’s, who may not have access to appropriate diagnostic tools, monitoring assays and who likely face difficulties accessing up to date knowledge and skills for best practice CML management. Our programs are designed to establish supportive relationships between international CML centers of excellence and clinicians worldwide, who have a significant commitment to CML patients.
Global Research
Working with the world’s leading experts, we’re answering the unanswered questions in CML.
iCMLf Cure Consortium
Hepatitis B and CML
Pediatric CML management in low and middle-income countries
Global Genomic Variation in CML
From the outset, the fundamental mission of the foundation has been to improve outcomes for CML patients globally, and that must be the guiding principle of anything that we do.
Professor Tim Hughes University of Adelaide, Australia
Bringing global researchers together to ensure more people with CML can stop therapy and sustain treatment free remission.
Investigating the impact of genomic variation on treatment response and outcomes.
